Humana (HUM) Updates FY18 Earnings Guidance

Humana (NYSE:HUM) updated its FY18 earnings guidance on Wednesday. The company provided earnings per share guidance of $13.50-14.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $12.45. The company issued revenue guidance of $55.8-56.4 billion, compared to the consensus revenue estimate of $56.57 billion.

Several equities research analysts have commented on the stock. Credit Suisse Group upgraded shares of Humana from a neutral rating to an outperform rating and decreased their target price for the stock from $264.90 to $246.00 in a research report on Thursday. Leerink Swann boosted their target price on shares of Humana from $280.00 to $300.00 and gave the stock an outperform rating in a research report on Thursday. Oppenheimer boosted their target price on shares of Humana from $275.00 to $305.00 and gave the stock an outperform rating in a research report on Thursday. Zacks Investment Research lowered shares of Humana from a strong-buy rating to a hold rating in a research report on Tuesday, October 17th. Finally, ValuEngine lowered shares of Humana from a buy rating to a hold rating in a research report on Tuesday, December 19th. Eight research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Humana presently has a consensus rating of Buy and an average price target of $268.26.

Humana (NYSE:HUM) opened at $262.37 on Friday. Humana has a one year low of $197.94 and a one year high of $293.35. The firm has a market cap of $37,843.64, a PE ratio of 22.66, a P/E/G ratio of 1.54 and a beta of 0.93. The company has a quick ratio of 1.61, a current ratio of 1.85 and a debt-to-equity ratio of 0.48.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share for the quarter, beating the consensus estimate of $2.00 by $0.06. Humana had a net margin of 4.55% and a return on equity of 16.13%. The firm had revenue of $13.19 billion during the quarter, compared to the consensus estimate of $13.14 billion. During the same quarter in the previous year, the company posted $2.34 EPS. The firm’s revenue for the quarter was up 2.4% on a year-over-year basis. equities analysts expect that Humana will post 13.75 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 27th. Stockholders of record on Friday, March 30th will be paid a dividend of $0.50 per share. The ex-dividend date is Wednesday, March 28th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.76%. This is an increase from Humana’s previous quarterly dividend of $0.40. Humana’s dividend payout ratio is currently 9.59%.

Humana declared that its board has approved a share buyback plan on Thursday, December 14th that authorizes the company to buyback $3.00 billion in shares. This buyback authorization authorizes the insurance provider to reacquire shares of its stock through open market purchases. Shares buyback plans are often an indication that the company’s board of directors believes its stock is undervalued.

In other news, VP Timothy S. Huval sold 1,382 shares of the company’s stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $246.04, for a total transaction of $340,027.28. Following the completion of the transaction, the vice president now owns 11,557 shares of the company’s stock, valued at approximately $2,843,484.28. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Brian P. Leclaire sold 1,679 shares of the company’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $245.97, for a total transaction of $412,983.63. Following the transaction, the senior vice president now directly owns 9,888 shares of the company’s stock, valued at approximately $2,432,151.36. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 10,115 shares of company stock valued at $2,501,627. Corporate insiders own 0.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.com-unik.info/2018/02/09/humana-hum-updates-fy18-earnings-guidance.html.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit